Figure 2.

Number of patients with psoriasis evaluated on the effectiveness of the treatment with muramyl peptide. The vertical scale and the numerical values in the figure represent Number of patients. A significant improvement was noted in 50 (58.1%) patients (42–with vulgar, 6–with exudative, and 2–with chronic psoriasis). Improvement of all clinical signs and symptoms in comparison with the initial condition was characteristic for 9 (10.4%) patients (5–with vulgar, 3–with exudative, and 1–with chronic psoriasis). Only 5 (5.9%) patients (in 2 with vulgar, 2 with exudative, and 1 with chronic psoriasis), the results of therapy were defined as satisfactory improvement. Deterioration during the pathological process was observed in 1 (1.2%) of a patient with a vulgar variety of a disease who had previously received systemic treatment with methotrexate.